The conversion of lycopene to apo‐10‐lycopenoic acid had significantly reduced lung cancer progression by lowering cyclin E and cell cycle modulation from the G1 to S phase, as well as by activating p21 and p27 (cell cycle regulating proteins) in NHBE (normal human bronchial epithelial cells), BEAS‐2B, and A549 lung cancer cells (von Lintig et al. 2020). Here, CDKN1A is linked to lung cancer.